Bacterial resistance to carbapenem agents has reached alarming levels. Accordingly,
collaborative efforts between national and international organizations and the …

Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat
(DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas …

ABSTRACT Cefiderocol (formerly S-649266) is a novel siderophore-conjugated
cephalosporin with activity against a broad array of multidrug-resistant (MDR), aerobic Gram …

Abstract Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore
cephalosporin that combines a catechol-type siderophore and cephalosporin core with side …

Carbapenem-resistant gram-negative bacteria including Enterobacteriaceae as well as
nonfermenters, such as Pseudomonas aeruginosa and Acinetobacter baumannii, have …

Introduction: The emergence of multidrug-resistant bacterial pathogens has led to a global
public health emergency and novel therapeutic options and drug-delivery systems are …

Abstract Intravenous cefiderocol (Fetroja®; Fetcroja®) is the first siderophore cephalosporin
approved for the treatment of adults with serious Gram-negative bacterial infections …

Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a
“Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity …

Cefiderocol (CFDC),(formerly S‐649266), is a novel injectable siderophore cephalosporin
developed by Shionogi & Co., Ltd., with potent in vitro activity against Gram‐negative …

The emergence of antimicrobial resistance is a significant public health issue worldwide,
particularly for healthcare-associated infections caused by carbapenem-resistant gram …